12 reports of this reaction
1.8% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE reports
#9 most reported adverse reaction
HYPERTENSION is the #9 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Foundation Consumer Brands. There are 12 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE to HYPERTENSION. This represents approximately 1.8% of all 662 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is a less commonly reported adverse event for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, but still significant enough to appear in the safety profile.
In addition to hypertension, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 12 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 1.8% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, making it a notable side effect.
If you experience hypertension while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.